Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
8392994
Reference Type
Journal Article
Title
Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer
Author(s)
Bitting, RL; Armstrong, AJ
Year
2013
Is Peer Reviewed?
Yes
Journal
Endocrine-Related Cancer
ISSN:
1351-0088
EISSN:
1479-6821
Volume
20
Issue
3
Page Numbers
R83-R99
Language
English
DOI
10.1530/ERC-12-0394
Abstract
The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is a key signaling pathway that has been linked to both tumorigenesis and resistance to therapy in prostate cancer and other solid tumors. Given the significance of the PI3K/Akt/mTOR pathway in integrating cell survival signals and the high prevalence of activating PI3K/Akt/mTOR pathway alterations in prostate cancer, inhibitors of this pathway have great potential for clinical benefit. Here, we review the role of the PI3K/Akt/mTOR pathway in prostate cancer and discuss the potential use of pathway inhibitors as single agents or in combination in the evolving treatment landscape of castration-resistant prostate cancer. Copyright © 2013 Society for Endocrinology.
Keywords
Akt; Androgen receptor signaling; Castration-resistant prostate cancer (CRPC); Combination therapy; MTOR; PI3K inhibitors; PI3K pathway
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity